| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The azide group of Biotin-PEG11-azide serves as a good leaving group and can participate in copper-catalyzed click reactions with alkynes. The biotin moiety provides high-affinity binding to streptavidin or avidin, enabling detection and purification of labeled biomolecules. The PEG spacer provides hydrophilicity and solubility.
|
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
In vitro activity is primarily related to its function as a biotinylation reagent via click chemistry. It enables the selective labeling of alkyne-containing biomolecules with biotin. The PEG spacer improves aqueous solubility and reduces nonspecific interactions. Biotinylated products can be detected using streptavidin-conjugated probes in ELISA, Western blot, or flow cytometry. |
| ln Vivo |
In vivo activity of Biotin-PEG11-azide is primarily inferred from its use in bioconjugation and imaging applications. Biotinylated molecules can be used for in vivo imaging or targeted delivery. The PEG spacer improves pharmacokinetic properties by increasing solubility and reducing immunogenicity. No direct in vivo activity data are specifically available for this linker alone.
|
| Enzyme Assay |
In vitro assays for Biotin-PEG11-azide typically involve evaluating its reactivity in click chemistry reactions with alkyne-containing molecules. Reaction efficiency is assessed by HPLC, mass spectrometry, or gel electrophoresis. Biotin incorporation is confirmed by streptavidin-binding assays such as ELISA or Western blot. Purity is assessed by HPLC (>95% typical). Solubility is evaluated in aqueous and organic solvents.
|
| Cell Assay |
Cell-based assays for Biotin-PEG11-azide involve labeling alkyne-modified biomolecules on cell surfaces or inside cells via click chemistry. Cells are incubated with alkyne-containing probes, followed by reaction with Biotin-PEG11-azide. Biotinylated products are detected using streptavidin-fluorophore conjugates by flow cytometry or fluorescence microscopy. Cytotoxicity is assessed by standard viability assays.
|
| Animal Protocol |
In vivo animal studies for Biotin-PEG11-azide are conducted in the context of bioorthogonal labeling or imaging. Mice are injected with alkyne-modified targeting probes followed by Biotin-PEG11-azide, or vice versa. Tissue distribution of biotinylated products is assessed by immunohistochemistry or imaging. Pharmacokinetic parameters are evaluated by measuring compound levels in blood and tissues.
|
| ADME/Pharmacokinetics |
As a PEG-based linker (molecular weight 796.98, formula C34H64N6O13S), Biotin-PEG11-azide is expected to have favorable aqueous solubility due to the hydrophilic PEG spacer. The PEG chain increases hydrodynamic volume and reduces renal clearance. No specific PK data are available for this linker alone; its PK profile is determined by the conjugated molecule.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data are specifically available for Biotin-PEG11-azide. The compound is for research use only and not intended for therapeutic or diagnostic use. Standard laboratory safety precautions should be followed. The azide group may present additional safety considerations; avoid heating or exposure to reducing agents that could generate toxic azide fumes.
|
| References | |
| Additional Infomation |
Biotin-PEG11-azide (CAS#: 956494-20-5) is a PEG derivative containing a biotin group and an azide group for click chemistry applications. It enables biotin labeling with precise spacing to alkyne-containing molecules. Molecular weight: 796.98, formula: C34H64N6O13S. It is for research use only and not an approved therapeutic agent.
|
| Molecular Formula |
C34H64N6O13S
|
|---|---|
| Molecular Weight |
796.969368934631
|
| Exact Mass |
406.242
|
| CAS # |
956494-20-5
|
| PubChem CID |
77078441
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-0.02
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
41
|
| Heavy Atom Count |
54
|
| Complexity |
960
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
S1CC2C(C1CCCCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])=O)NC(N2)=O
|
| InChi Key |
WETRQYMCASPBIY-PHDGFQFKSA-N
|
| InChi Code |
InChI=1S/C34H64N6O13S/c35-40-37-6-8-44-10-12-46-14-16-48-18-20-50-22-24-52-26-28-53-27-25-51-23-21-49-19-17-47-15-13-45-11-9-43-7-5-36-32(41)4-2-1-3-31-33-30(29-54-31)38-34(42)39-33/h30-31,33H,1-29H2,(H,36,41)(H2,38,39,42)/t30-,31-,33-/m0/s1
|
| Chemical Name |
5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]pentanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2548 mL | 6.2738 mL | 12.5475 mL | |
| 5 mM | 0.2510 mL | 1.2548 mL | 2.5095 mL | |
| 10 mM | 0.1255 mL | 0.6274 mL | 1.2548 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
